TheraRadar
← Back
Data updated: May 24, 2026

ACCORD HLTHCARE

Generics

ACCORD HLTHCARE is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology.

1972
Since
138
Drugs
-
Trials
4
New Drugs (2yr)
Modality:
1 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 40%
17 drugs
Cardiovascular 28%
12 drugs
Neurology 21%
9 drugs
Gastroenterology 7%
3 drugs
Infectious Disease 5%
2 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling